131 related articles for article (PubMed ID: 37023875)
1. Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway.
Qin P; Yan J; Huang H; Wang Q; Li M; Zhang Y; Wang J; Jiang T; Zhang X; Zhou Y
Int J Biol Macromol; 2023 Jun; 241():124323. PubMed ID: 37023875
[TBL] [Abstract][Full Text] [Related]
2. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
Wang H; Chen M; Yang C; Hu H; Jiang Y; Yang F; Lv L
Arch Biochem Biophys; 2023 Jul; 743():109661. PubMed ID: 37268273
[TBL] [Abstract][Full Text] [Related]
3. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
4. LncRNA RHPN1-AS1 Promotes Cell Proliferation, Migration and Invasion Through Targeting miR-7-5p and Activating PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma.
Song XZ; Ren XN; Xu XJ; Ruan XX; Wang YL; Yao TT
Technol Cancer Res Treat; 2020; 19():1533033820957023. PubMed ID: 32910747
[TBL] [Abstract][Full Text] [Related]
5. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
7. Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.
Cai T; Bai J; Tan P; Huang Z; Liu C; Wu Z; Cheng Y; Li T; Chen Y; Ruan J; Gao L; DU Y; Fu W
Oncol Res; 2023; 31(5):805-817. PubMed ID: 37547758
[TBL] [Abstract][Full Text] [Related]
8. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].
Shang L; Jiang W; Zhang J; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
10. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
11. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
12. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
13. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
14. circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway.
Wu C; Tian S; Guo Y; Yu C; Lei L; Zheng D; Xie H; Zheng J; Sun C
J Immunol Res; 2022; 2022():8649386. PubMed ID: 35769514
[TBL] [Abstract][Full Text] [Related]
15. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.
Li K; Fan T; Shi Z; Jiang H
Anal Cell Pathol (Amst); 2022; 2022():9912254. PubMed ID: 36588796
[TBL] [Abstract][Full Text] [Related]
16. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
[TBL] [Abstract][Full Text] [Related]
17. miR-21-5p Inhibits Ferroptosis in Hepatocellular Carcinoma Cells by Regulating the AKT/mTOR Signaling Pathway through MELK.
Hu Z; Li L; Li M; Zhang X; Zhang Y; Ran J; Li L
J Immunol Res; 2023; 2023():8929525. PubMed ID: 37008632
[TBL] [Abstract][Full Text] [Related]
18. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
19. TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma.
Yin YT; Shi L; Wu C; Zhang MY; Li JX; Zhou YF; Wang SC; Wang HY; Mai SJ
Med Oncol; 2024 Feb; 41(3):79. PubMed ID: 38393440
[TBL] [Abstract][Full Text] [Related]
20. MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway.
Wang L; Cui M; Qu F; Cheng D; Yu J; Tang Z; Cheng L; Wei Y; Wu X; Liu X
Curr Pharm Des; 2021; 27(29):3244-3250. PubMed ID: 34126886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
